Sound shipResMed $RMD
Grew revenue 9.9% in FY2026 to $5.7 billion, operating margin 33.4% against a 1.2% median for surgical & medical instruments & apparatus, equity 73.4% of assets, and dividend per share up 5 years running.
Last filing10-Q, 30 Oct 2026
Edgarette’s full reading · exposure, experience, soundness, credibility, range
🫧 Edgar looked up ResMed Inc. ($RMD). Last filing: 10-Q, 2026-10-30. 9 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-08-17.
🔖 Exposure: revenue $5.7B (FY2026), total debt $399.4M. Experience: revenue up 9.9% on the year, up 12.1% a year over 4 years; operating margin 33.4%, up from 32.7%. Soundness: equity 73.4% of assets, return on equity 23.1%, payout 23.0% of profit, dividend per share up 5 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.6B and $6.6B next year (method v4.1: its own 5-year record of growth weighed at 57% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.3B to $7.0B. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 33.4% against a 1.2% median; growth 9.9% against 11.6%.
Read from its own SEC filings · nothing written, nothing inferred
Gold paid out, navy kept. Kept share × return on equity = the growth it can fund itself. Facts from the filings, not a recommendation.
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | $1.8B · −$545M · −$1.0B · $1.6B |
| Investment book (cash · short · long) | $1.5B · — · — · current ratio 3.10 |
| Revenue swing · equity of assets | 3.2% · 74.3% |
ResMed is growing faster than its size class, with steadier revenue. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2026-06-30 |
| Revenue | $5.7B |
| Revenue, on the year | 9.9% |
| Revenue, a year over the record | 12.1% |
| Operating margin | 33.4% |
| Operating margin, prior year | 32.7% |
| Net margin | 26.9% |
| Research and development | $378M · 6.7% of revenue |
| Total debt | $399M |
| Equity of assets | 73.4% |
| Return on equity | 23.1% |
| Payout of profit | 23.0% |
| Dividend per share | $2.4 · up 5 years running |
| Earnings per share | $10.47 |
| Book value per share | $45.09 |
| Revenue per share | $38.71 |
| Shares outstanding | 146,054,000 |
| Audited years read | 5 |
Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.
Classic signals · fiscal 2026Altman Z″ 9.1 safe zone 1968Piotroski F 7 of 9 solid 2000Beneish M -2.58 below the −1.78 line 1999Sloan accruals -3.3% earnings backed by cash 1996DuPont ROE 24.3% = margin 26.9% × turns 0.66 × leverage 1.37
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health HarborResMed sails as: Sound ship
Health watch · 12 monthsAuditor changeDirector or officer change ×3
Sailing speed follows growth: 12.9% a year crosses the harbor in 41 seconds.
🌊 Visit the Bay →- filed auditor change in the last 12 months
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Brand success factors · calendar 2025
The Trillion Score: 518
Exponential Success Score
Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.
How The Trillion Score works. We read eight measures of success from ResMed's own SEC filings and test each one against the public companies in its field, here surgical & medical instruments & apparatus. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.
What it says here. At 518, ResMed's odds of thriving come to 39%, against about 37% for the typical filer. It meets 2 of 8 success points.
What the score means
The higher the score, the more often companies went on to thrive. At this level, about 38 of every 100 did.
Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.
Fall Risk: Medium
Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 22 of every 100 companies in the Medium band did. That is the group's history, not a forecast for this company.
| Money | It keeps about 32 cents of free cash from each sales dollar after paying for its plants and equipment. It holds more cash than debt. | low |
| Swings | Even in its worst years on record, sales still grew. | 7.8% a year |
| Filed events | In the last two years it told the SEC about 4 filings on leadership or auditor changes. | 4 |
The eight success points
| Point | What it means | Place in field | |
|---|---|---|---|
| Speed | Sales grew slower than much of its field. | 59 of 100 | Not yet |
| Steadiness | Growth was strong for how much it swung, so it looks dependable. | 99 of 100 | Met |
| Price premium | It keeps less of each sales dollar than the leaders in its field. | 47 of 100 | Not yet |
| Margin stays above the field | Its margin has not held above the field for long. | 17 of 100 | Not yet |
| Moat half-life | Its margin edge is fading fast, or it has none yet. | 25 of 100 | Not yet |
| Brand spend yield | Brand spending returns more gross profit than for most of its field. | 89 of 100 | Met |
| Learning curve | Costs have not fallen much as a share of sales as it grew. | 56 of 100 | Not yet |
| Climb in the field | It has not been moving up the size ranks in its field. | 58 of 100 | Not yet |
Price premium -$55M is the extra gross profit over a field-median margin. Momentum $91M is gross profit times growth above the field's pace.
The actuarial view
| Credibility | With 8 years of filings, the record earns 70% of the weight. The rest stays at the middle of the field. | 0.70 |
| Severe decline, class C | About 30 of every 100 companies with this many points fell 30% or stopped reporting within three years. | 30.1% |
| Actual vs expected | Sales are 9% higher than if it had simply kept pace with its field. | 1.09 |
Top of its field: #1 SANUWAVE Health · #2 AVITA Medical · #3 TELA Bio · #4 Inspire Medical Systems · #5 Insulet
Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.
- 10-Q · 2026-10-30
- 8-K · 2026-10-29 · 2.02 Results of Operations and Financial Condition; 8.01 Other Events; 9.01 Financial Statements and Exhibits
- DEF 14A · 2026-10-01
- 8-K · 2026-09-01 · 8.01 Other Events
- 8-K · 2026-08-17 · 4.01 Changes in Registrant's Certifying Accountant; 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 10-K · 2026-08-13
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.
Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·